|55 Kenosia Avenue
Danbury, CT 06810
Toll Free: 1.800.999.6673
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
Copyright 1994, 2003
Essential iris atrophy is a very rare, progressive disorder of the eye characterized by a pupil that is out of place and/or distorted areas of degeneration on the iris (atrophy), and/or holes in the iris. This disorder most frequently affects only one eye (unilateral) and develops slowly over time. Attachment of portions of the iris to the cornea (peripheral anterior synechiae) and/or abnormalities in the cornea may lead to secondary glaucoma and vision loss.
Essential iris atrophy is one of three iridocorneal endothelial (ICE) syndromes, each of which usually affects one eye of young to middle-aged men and women. The ICE syndromes (essential iris atrophy, Chandler syndrome, and Cogan-Reese syndrome) are distinct from one another. However, these disorders all affect the eye. Some of their symptoms overlap, making it difficult to distinguish between them.
Major symptoms of essential iris atrophy may include a displaced and/or distorted pupil, patchy areas of degeneration (atrophy) on the iris, and/or holes in the iris. The edge of the pupil may turn outward (ectropion uveae). The onset of this disorder is gradual, and the changes in the shape and placement of the pupil are usually noticed before any change in vision occurs. Degeneration and holes in the iris may develop over a period of several years.
Other features of essential iris atrophy may include the attachment of portions of the iris to the cornea (peripheral anterior synechiae), swelling of the cornea (corneal edema), and/or abnormalities in the cells lining the cornea (corneal endothelium). These changes may lead to increased pressure in the eye (glaucoma) and vision loss.
The cause of essential iris atrophy or any other of the iridocorneal endothelial syndromes is not known. They are thought to be the result of the same mechanism and, according to one theory, a particular membrane (the corneal endothelial membrane) is the site of the primary defect. This idea proposes that the primary disorder is of the cells that line the cornea (corneal endothelium), with the impact on the iris and associated glaucoma as secondary or associated disorders.
Other researchers suspect that inflammation or chronic infection may be the cause of the disease.
Essential iris atrophy is a very rare disorder that is usually recognized in early to middle adulthood and occurs slightly more often among women than among men.
Symptoms of the following disorders can be similar to those of essential iris atrophy. Comparisons may be useful for a differential diagnosis:
Chandler's syndrome is a rare disorder characterized by increased development in the cells lining the cornea, drying up of the iris, corneal swelling (edema), and unusually high pressure in the eye (glaucoma). This disorder may result in vision loss. The displacement and/or distortion of the pupil characteristic of essential iris atrophy does not occur in Chandler's Syndrome. (For more information on this disorder, choose "Chandler" as your search term in the Rare Disease Database.)
Cogan-Reese syndrome is an extremely rare disorder characterized by loss of iris tissue and the development of small wart-like growths on the iris. Increased pressure within the eye (glaucoma) and corneal swelling (edema) are also evident. This disorder differs from Cogan corneal dystrophy which is inherited as an autosomal dominant disorder. The displacement and/or distortion of the pupil characteristic of essential iris atrophy does not occur in Cogan-Reese syndrome. (For more information on this disorder, choose "Cogan-Reese" as your search term in the Rare Disease Database.)
The following disorders may be associated with essential iris atrophy as secondary characteristics. They are not necessary for a differential diagnosis:
Glaucoma is a common eye disorder that occurs as a secondary disorder to essential iris atrophy. Glaucoma is characterized by increased pressure within the eye. If left untreated the increased pressure may affect the lens and the optic nerve, resulting in eventual blindness. Glaucoma usually occurs for unknown reasons, however, it is more prevalent in people with diabetes. Some symptoms to be aware of are blurred vision, rainbow-colored halos around lights, and loss of side vision (tunnel vision). A simple test can measure the pressure in an individual's eye, and this testing is recommended annually for persons over age forty. Treatment may consist of medicated eye drops. If medication does not resolve the symptoms surgery may be necessary.
Treatment of essential iris atrophy is usually directed to the secondary glaucoma. Eye drops may be used to control the glaucoma and corneal swelling (edema). If these methods are unsuccessful surgery may be indicated. The use of a laser beam to reduce pressure within the eye (trabeculectomy) and corneal transplant (penetrating keratoplasty) are surgical methods that have been used to treat essential iris atrophy.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Kanski JJ. Ed. Clinical Ophthalmology. 4th ed. Butterworth-Heinemann. Oxford, UK; 1999:232-34.
Newell FW. Ed. Ophthalmology: Principles and Concepts. 7th ed. Mosby Year Book, St. Louis, MO; 1991:275-76.
Lakosha HM, Pavlin CJ, Simpson ER. Essential Iris atrophy mimicking iris neoplasm: an ultrasound biomicroscopic study. Can J Ophthalmol. 2000;35:390-93.
Howell DN, Damms T, Burchette JL Jr, et al. Endothelial metaplasia in the iridocorneal endothelial syndrome. Invest Ophthalmol Vis Sci. 1997;38:1896-901.
Huna R, Barak A, Melamed S. Bilateral iridocorneal endothelial syndrome presented as Cogan-Reese and Chandler's syndrome. J Glaucoma;1996;5:60-62.
DeBroff BM, Thoft RA. Surgical Results of penetrating keratoplasty in essential iris atrophy. J Refract Corneal Surg. 1994;10:428-32.
Alvarado JA, Murphy CG, Juster RP, et al. Pathogenesis of Chandler's syndrome, essential iris atrophy and the Cogan-Reese syndrome. II. Estimated age at disease onset. Invest Ophthalmol Vis Sci. 1986;27:873-82.
Alvarado JA, Murphy CG, Maglio M, et al. Pathogenesis of Chandler's syndrome, essential iris atrophy and the Cogan-Reese syndrome. I. Alterations of the corneal endothelium. Invest Ophthalmol Vis Sci. 1986;27:853-72.
FROM THE INTERNET
Kaiser P. Iridocorneal Endothelial (ICE) Syndromes. Digital Journal of Ophthalmology (DJO). nd. 2pp.
Devine N. (ed.) Monday Night Chat Room. Wills Glaucoma Service & Foundation. Glaucoma. nd. 5pp.
Burk R. Classification of secondary glaucomas.
Report last updated: 2008/04/17 00:00:00 GMT+0